<DOC>
	<DOCNO>NCT00579956</DOCNO>
	<brief_summary>Melioidosis , infection cause bacterium Burkholderia pseudomallei , major cause community-acquired septicaemia northeast Thailand . Common manifestation include cavitating pneumonia , hepatic splenic abscess , soft tissue joint infection . Despite improvement diagnostic procedure treatment , mortality severe melioidosis remain unacceptably high - approximately 35 % currently use antibiotic ( ceftazidime co-amoxiclav ) . There clear evidence antibiotic affect mortality ; use ceftazidime rather previous regimen ( doxycycline + chloramphenicol + co-trimoxazole ) lead 50 % reduction mortality 80 % 35 % . However , mortality first 48 hour alter treatment regimen . A key question whether alternative antibiotic could improve early outcome . The hypothesis test meropenem superior ceftazidime term mortality treatment melioidosis .</brief_summary>
	<brief_title>A Randomized Double Blinded Comparison Ceftazidime Meropenem Severe Melioidosis</brief_title>
	<detailed_description>Mortality rate patient severe melioidosis still unacceptably high . Response high dose parenteral ceftazidime treatment survivor also slow , median time abatement fever approximately 9 day . B. pseudomallei susceptible ceftazidime , imipenem , co-amoxiclav ( Augmentin® ) , piperacillin doxycycline , unlike pseudomonad resistant aminoglycosides , apart kanamycin borderline activity . The fluoroquinolone compound also borderline activity . Two large publish in-vitro study show carbapenem group active antibiotic B. pseudomallei , MIC90 0.5 1.0 mg/L , MBC90 1 mg/L . We test susceptibility meropenem 100 recently isolate strain B. pseudomallei , assess susceptible ( MIC90 = 0.5 mg/L ; range 0.125-1 mg/L ) . Furthermore , 13 isolates collection assess resistant ceftazidime susceptible meropenem . Using time-kill kinetic study , ceftazidime show `` significant '' bactericidal activity whereas meropenem bactericidal ( 99.9 % kill ) within 6 hour . Previous treatment trial demonstrate importance choice antibiotic time presentation . A study compare four-drug combination chloramphenicol , doxycycline , trimethoprimsulfamethoxazole ( TMP-SMX ) ceftazidime alone demonstrate 50 % reduction mortality rate 80 % 35 % . Several previous randomize controlled trial conduct determine whether administration alternative antimicrobial drug associated improvement outcome . A comparison TMP-SMX plus ceftazidime versus ceftazidime alone demonstrate addition TMPSMX reduce acute mortality rate . A previous study compare ceftazidime imipenem/cilastatin treatment severe melioidosis perform Ubon Ratchathani 1994 1997 . This show `` treatment failure '' rate ( potentially subjective endpoint open-labelled trial ) imipenem/cilastatin group low ceftazidime group . Endotoxin release , believe important pathogenesis severe sepsis , also low imipenem group ceftazidime group . No difference mortality observe , study underpowered follow early termination due lack imipenem supply manufacturer . As result , ceftazidime remain treatment choice melioidosis , question remain whether carbapenem drug would effective . A second , sufficiently power clinical trial would address important question .</detailed_description>
	<mesh_term>Melioidosis</mesh_term>
	<mesh_term>Meropenem</mesh_term>
	<mesh_term>Thienamycins</mesh_term>
	<mesh_term>Ceftazidime</mesh_term>
	<criteria>Inclusion criterion ( criterion must satisfy ) A . Community acquire sepsis , melioidosis suspect : Suspected melioidosis ( 12 ) : follow define 'clinically probable ' melioidosis A history frequent contact soil surface water endemic area At least one follow risk factor : diabetes mellitus , chronic renal failure renal calculus , thalassaemia , aplastic anaemia steroid abuse An illness compatible melioidosis , include presence sepsis , acute pneumonia , acute pyelonephritis , septic arthritis , parotid disease skin soft tissue infection , An evidence intraabdominal suppuration ( hepatic splenic abscess ) regardless risk factor exposure history Sepsis : defined patient Systemic Inflammatory Response Syndrome ( SIRS ) two follow , clinically ascribed infection : Fever : temperature &gt; 38°C &lt; 36°C Tachycardia : heart rate &gt; 90 beats/min Tachypnoea : 1 . Respiratory rate &gt; 20 breaths/minute ; 2 . PaCO2 &lt; 32 mmHg ; 3 . Mechanical ventilation White cell count &gt; 12,000 cells/mL &lt; 4,000 cells/mL &gt; 10 % band form B . Age &gt; 14 year . C. Need hospitalisation intravenous antibiotic administration . D. Willingness participate study write , informed consent obtain patient . Exclusion Criteria ( one follow ) : A . Pregnant lactating woman . B . Known hypersensitivity meropenem ceftazidime . C. Previous isolate know resistance ceftazidime meropenem . D. Patients expect remain hospital treatment . E. Patients communityacquired sepsis culture positive organism . F. Patients treat antibiotic active B. pseudomallei ( include ceftazidime , amoxicillinclavulanate , meropenem ) episode great 24 hour .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
</DOC>